ARCTURUS THERAPEUTICS HOLDINGS INC. Form 8-K (Oct. 27, 2021)

Summary

Current report on Form 8-K of Arcturus Therapeutics Holdings Inc., date of report October 27, 2021, filed under Item 1.01. It states that on October 27, 2021 Arcturus Therapeutics, Inc., a wholly owned subsidiary, and Western Alliance Bank entered into a Fifth Amendment to the Loan and Security Agreement dated October 12, 2018. Under the amendment the Borrower agreed to make monthly interest-only payments through the payment date preceding May 1, 2022. Commencing on May 1, 2022, the Borrower shall make consecutive equal monthly payments of principal with interest, calculated by the Bank on the term loan amount, the effective rate of interest and a repayment schedule equal to eighteen (18) months. The signature block shows /s/ Joseph E. Payne, dated November 1, 2021.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 27, 2021

ARCTURUS THERAPEUTICS HOLDINGS INC.

(Exact name of registrant as specified in its
charter)

Delaware | 001-38942 | 32-0595345
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.)

10628 Science Center Drive , Suite 250

San Diego , California 92121

(Address of principal executive offices)

Registrant’s telephone number, including
area code: (858) 900-2660

(Former name or former address, if changed since
last report)

Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common stock, par value $0.001 per share | ARCT | The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement.

On October 27, 2021, Arcturus Therapeutics, Inc. (“Arcturus”),
a wholly-owned subsidiary of Arcturus Therapeutics Holdings Inc., and Western Alliance Bank (the “Bank”) entered into a Fifth
Amendment (the “Fifth Amendment”) to the Loan and Security Agreement dated October 12, 2018 (the “Loan Agreement”)
between the Bank and the Borrower.

Pursuant to the Fifth Amendment, the Borrower agreed to make monthly
payments of interest only on each payment date through and including the payment date immediately preceding May 1, 2022. Commencing on
May 1, 2022, and continuing on the payment date of each month thereafter, the Borrower shall make consecutive equal monthly payments of
principal, together with applicable interest, in arrears, to the Bank, as calculated by the Bank based upon: (1) the amount of the term
loan, (2) the effective rate of interest, and (3) a repayment schedule equal to eighteen (18) months.

The foregoing description of the terms of the Fifth Amendment does
not purport to be complete and is qualified in its entirety by reference to the full text of the Fifth Amendment, which will be filed
with the Securities and Exchange Commission (the “Commission”) as an exhibit to Arcturus’ Quarterly Report on Form 10-Q
for the quarter ended September 30, 2021.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. | Description of Exhibit
104 | Cover Page to this Current Report on Form 8-K in Inline XBRL

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Arcturus Therapeutics Holdings Inc.
Date: November 1, 2021
By: | /s/ Joseph E. Payne
Name: | Joseph E. Payne
Title: | Chief Executive Officer

File and source

File

SEC_ARCT_8-K_filed2021-11-01_0001193805-21-001517.htm

Size

22,607 bytes

SHA-256

37fa07f0e049da5a485f8d74e0663f6b91290c7a54e7a3224985b1a97a17cc95

Our copy

SEC_ARCT_8-K_filed2021-11-01_0001193805-21-001517.htm

Original

www.sec.gov